|
[1] JEMAL A,BRAY F,CENTER MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
|
|
[2]FU X,HE J,SHI J,et al.Clinical value of morphological classification of hepatocellular carcinoma[J].Chin J Dig Surg,2015,14(2):120-126.(in Chinese)伏旭,何健,史烔,等.肝细胞癌大体形态分型的临床意义[J].中华消化外科杂志,2015,14(2):120-126.
|
|
[3] LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
|
|
[4]CHENG AL,KANG YK,CHEN Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
|
|
[5]FAIVRE S,RAYMOND E,BOUCHER E,et al.Safety and efficacy of sunitinib in patients with advanced hepato cellularcarcinoma:an open-label,multicentre,phaseⅡstudy[J].Lancet Oncol,2009,10(8):794-800.
|
|
[6]CHENG A,KANG Y,LIN D,et al.PhaseⅢtrial of sunitinib versus sorafenib in advanced hepatocellular carcinoma(HCC)[J].J Clin Oncol,2011,29(15):2696.
|
|
[7]QI XS,JIA J,HAN GH,et al.Sunitinib for Treatment of Hepatocellular Carcinoma:an Overview of Clinical Trials[J].Chin J Gastroenterol,2014,19(3):169-172.(in Chinese)祁兴顺,贾佳,韩国宏,等.舒尼替尼治疗肝细胞癌的临床研究现状[J].胃肠病学,2014,19(3):169-172.
|
|
[8]BRUIX J,TAK WY,GABARRINI A,et al.Regorafenib as secondline therapy for intermediate or advanced hepatocellular carcinoma:multicentre,open-label,phaseⅡsafety study[J].Eur J Cance,2013,49(16):3412-3419.
|
|
[9]CHENG AL,FINNR S,KUDO M,et al.Regorafenib(REG)in patients with hepatocellular carcinoma(HCC)progressing following sorafenib:an ongoing randomized,doubleblind,phaseⅢtrial[J].J Clin Oncol,2013,31(Suppl 15):4163.
|
|
[10]QI XS,JIA J,LIU L,et al.Regorafenib for treatment of hepatocellular carcinoma:an overview of clinical trials[J].J Clin Hepatol,2014,30(3):225-227.(in Chinese)祁兴顺,贾佳,刘雷,等.Regorafenib治疗肝癌的临床研究进展[J].临床肝胆病杂志,2014,30(3):225-227.
|
|
[11]TOH HC,CHEN PJ,CARR BI,et al.Phase 2 trial of linifanib(ABT-869)in patients with unresectable or metastatic hepatocellular carcinoma[J].Cancer,2013,119(2):380-387.
|
|
[12]CAINAP C,QI S,HUANG WT,et al.Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma:results of a randomized phaseⅢtrial[J].J Clin Oncol,2015,33(2):172-179.
|
|
[13]HU FR,GAO F,QI XS.Advances in clinical research on linifanib in treatment of liver cancer[J].World Chin J Dig,2015,23(16):2568-2573.(in Chinese)胡凤蓉,高帆,祁兴顺.Linifanib治疗肝癌的临床研究进展[J].世界华人消化杂志,2015,23(16):2568-2573.
|
|
[14]PHILIP PA,MAHONEY MR,ALLMER C,et al.Phase II study of Erlotinib(OSI-774)in patients with advanced hepatocellular cancer[J].J Clin Oncol,2005,23(27):6657-6663.
|
|
[15]ZHU AX,ROSMORDUC O,EVANS TR,et al.SEARCH:a phase III,randomized,doubleblind,placebocontrolled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma[J].J Clin Oncol,2015,33(6):559-566.
|
|
[16]GAO F,QI XS.Clinical research progress in Erlotinib treatment for hepatocellular carcinoma[J].J Clin Hepatol,2015,31(6):985-988.(in Chinese)高帆,祁兴顺.Erlotinib治疗肝癌的临床研究进展[J].临床肝胆病杂志,2015,31(6):985-988.
|
|
[17]JOJNSON PJ,QIN S,PARK JW,et al.Brivanib versus sorafenib as first-line therapy in patients with unresectable,advanced hepatocellular carcinoma:results from the randomized phaseⅢBRISK-FL study.[J].J Clin Oncol,2013,31(28):3517-3524.
|
|
[18]LLOVET JM,DECAENS T,RAOUL JL,et al.Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed:results from the randomized phaseⅢBRISK-PS study[J].J Clin Oncol,2013,31(28):3509-3516.
|
|
[19]QI XS,YANG M,BAI W,et al.Brivanib for treatment of hepatocellular carcinoma:an overview of clinical trials[J].J Clin Hepatol,2014,30(3):222-224.(in Chinese)祁兴顺,杨曼,白苇,等.Brivanib治疗肝癌的临床研究进展[J].临床肝胆病杂志,2014,30(3):222-224.
|
|
[20]SANTORO A,RIMASSA L,BORBATH I,et al.Tivantinib for second-line treatment of advanced hepatocellular carcinoma:a randomised,placebo-controlled phase 2 study[J].Lancet Oncol,2013,14(1):55-63.
|
|
[21]QI XS,GUO XZ,HAN GH,et al.MET inhibitors for treatment of advanced hepatocellular carcinoma:a review[J].World J Gastroenterol,2015,21(18):5445-5453.
|
|
[22]SANTORO A,PORTA C,RIMASSA L,et al.Metiv-HCC:a phaseⅢclinical trial evaluating tivantinib(ARQ 197),a MET inhibitor,versus placebo as second-line in patients(pts)with MET-high inoperable hepatocellular carcinoma(HCC)[C]//ALEXANDRIA,VA 22314 USA:ASCO,2013,31(15).
|
|
[23]GOVINAERAJAN R,SIEGEL E,MAKHOUL I,et al.Bevacizumab and erlotinibin previously untreated inoperable and metastatic hepatocellular carcinoma[J].Am J Clin Oncol,2013,36(3):254-257.
|
|
[24]QIN S,BAI Y,LIM HY,et al.Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol,2013,31(28):3501-3508.
|
|
[25]ZHAO Y,WANG WJ,GUAN S,et al.Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma:a large-scale multicenter study of 222 patients[J].Ann Oncol,2013,24(7):1786-1792.
|
|
[26]BRUIX J,TAKAYANA T,MAZZAFERRO V,et al.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation(STORM):a phase 3,randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2015,16(13):1344-1354.
|
DownLoad: